Clinical Trial Update: Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of YM150, a direct Factor Xa inhibitor from Astellas, for prevention of stroke in non-valvular atrial fibrillation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-valvular Atrial Fibrillation

Drugs mentioned

• YM150

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Atrial Fibrillation | Phase 2 | Status: COMPLETED